دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
How epidemiology can improve the understanding of cardiovascular disease: from mechanisms to treatment
Filippo Crea
doi : 10.1093/eurheartj/ehab797
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4503–4507
Heartfelt welcome to ESC 2021
Mark Nicholls
doi : 10.1093/eurheartj/ehab661
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4508–4509
Healing the rift over left main revascularization
Nicholls Mark
doi : 10.1093/eurheartj/ehab675
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4509–4511
Diverse topics tackled by latest ‘hot’ research
Mark Nicholls
doi : 10.1093/eurheartj/ehab685
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4512–4514
A new era for the European Heart Journal
doi : 10.1093/eurheartj/ehab655
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4515–4517
The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehab647
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4518–4519
Wine, chocolate, and coffee: forbidden joys?
Thomas F Lüscher
doi : 10.1093/eurheartj/ehab654
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4520–4522
Genome-wide association study identifies 18 novel loci associated with left atrial volume and function
Gustav Ahlberg, Laura Andreasen, Jonas Ghouse, Litten Bertelsen, Henning Bundgaard, Stig Haunsø, Jesper H Svendsen, Morten S Olesen
doi : 10.1093/eurheartj/ehab466
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4523–4534
Left atrial (LA) volume and function impose significant impact on cardiovascular pathogenesis if compromised. We aimed at investigating the genetic architecture of LA volume and function using cardiac magnetic resonance imaging data.
Genetics, atrial cardiomyopathy, and stroke: enough components for a sufficient cause?
Stephan Camen, Renate B Schnabel
doi : 10.1093/eurheartj/ehab523
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4533–4535
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
Uwe Zeymer, Peter Ludman, Nicolas Danchin, Petr Kala, Cécile Laroche, Masoumeh Sadeghi, Roberto Caporale, Sameh Mohamed Shaheen, Jacek Legutko, Zaza Iakobsishvili, Khalid F Alhabib, Zuzana Motovska, Martin Studencan, Jorge Mimoso, David Becker, Dimitrios Alexopoulos, Zviad Kereseselidze, Sinisa Stojkovic, Parounak Zelveian, Artan Goda, Erkin Mirrakhimov, Gani Bajraktari, Hasan Al-Farhan, Pranas Šerpytis, Bent Raungaard, Toomas Marandi, Alice May Moore, Martin Quinn, Pasi Paavo Karjalainen, Gabriel Tatu-Chitolu, Chris P Gale, Aldo P Maggioni, Franz Weidinger, the ACVC EAPCI EORP ACS STEMI investigators group of the ESC
doi : 10.1093/eurheartj/ehab342
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4536–4549
The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI).
ST-segment elevation myocardial infarction management: great strides but still room for improvement
Cindy L Grines, Sameer Mehta
doi : 10.1093/eurheartj/ehab596
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4550–4552
Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study
Jeppe Kofoed Petersen, Jawad Haider Butt, Adelina Yafasova, Christian Torp-Pedersen, Rikke Sørensen, Christina Kruuse, Naja Emborg Vinding, Anna Gundlund, Lars Køber, Emil Loldrup Fosbøl, Lauge Østergaard
doi : 10.1093/eurheartj/ehab575
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4553–4561
The aim of this study was to examine contemporary data on the 1-year prognosis of patients surviving acute coronary syndrome (ACS) and concomitant first-time detected atrial fibrillation (AF).
Known or new atrial fibrillation in patients with acute coronary syndrome: what’s the difference?
W L Bor, J M ten Berg
doi : 10.1093/eurheartj/ehab689
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4562–4564
Physical activity and fitness in the community: the Framingham Heart Study
Matthew Nayor, Ariel Chernofsky, Nicole L Spartano, Melissa Tanguay, Jasmine B Blodgett, Venkatesh L Murthy, Rajeev Malhotra, Nicholas E Houstis, Raghava S Velagaleti, Joanne M Murabito, Martin G Larson, Ramachandran S Vasan, Ravi V Shah, Gregory D Lewis
doi : 10.1093/eurheartj/ehab580
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4565–4575
While greater physical activity (PA) is associated with improved health outcomes, the direct links between distinct components of PA, their changes over time, and cardiorespiratory fitness are incompletely understood.
Don’t count the steps: make the steps count? Digging deeper into physical activity and fitness
Jon Magne Letnes, Bjarne M Nes
doi : 10.1093/eurheartj/ehab716
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4576–4577
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
Eun Ha Kang, Eun Hye Park, Anna Shin, Jung Soo Song, Seoyoung C Kim
doi : 10.1093/eurheartj/ehab619
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4576–4577
With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents. We compared CV risk among patients with gout who initiated allopurinol vs. benzbromarone.
Gout, urate-lowering drugs, and risk of cardiovascular disease: can we clinically trust in the adjusted real-life data?
Claudio Borghi, Giulia Fiorini
doi : 10.1093/eurheartj/ehab667
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4589–4591
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group
Hiroaki Shimokawa, Akira Suda, Jun Takahashi, Colin Berry, Paolo G Camici, Filippo Crea, Javier Escaned, Tom Ford, Eric Yii, Juan Carlos Kaski, Takahiko Kiyooka, Puja K Mehta, Peter Ong, Yukio Ozaki, Carl Pepine, Ornella Rimoldi, Basmah Safdar, Udo Sechtem, Kenichi Tsujita, Satoshi Yasuda, John F Beltrame, C Noel Bairey Merz on behalf of the Coronary Vasomotor Disorders International Study (COVADIS) Group
doi : 10.1093/eurheartj/ehab282
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4592–4600
To provide multi-national, multi-ethnic data on the clinical characteristics and prognosis of patients with microvascular angina (MVA).
Microvascular angina: quo tendimus?
Ranil de Silva, Kevin Cheng
doi : 10.1093/eurheartj/ehab534
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Pages 4601–4604
Carney complex featuring giant intracardiac biatrial myxoma in an adolescent girl
Ventsislav Sheytanov, Heike Schaefer, Peter Hitzle, Robert Nossal, Frank Uhlemann, Iannis Tzanavaros, Fabian Spoehr, Joerg Seeburger
doi : 10.1093/eurheartj/ehaa1047
European Heart Journal, Volume 42, Issue 44, 21 November 2021, Page 4605
